- Stocks
- Healthcare
- NASDAQ: INVA

Price (delayed)

$14.44

Market cap

$925.41M

P/E Ratio

17.83

Dividend/share

N/A

EPS

$0.81

Enterprise value

$1.19B

Innoviva, Inc. is a healthcare focused asset management company. The Company intends to participate in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva operates in the United States.

The debt has contracted by 17% YoY

Innoviva's quick ratio has increased by 6% from the previous quarter

The equity has increased by 13% since the previous quarter but it has declined by 2.2% year-on-year

The stock's price to earnings (P/E) is 158% more than its last 4 quarters average of 6.9

INVA's net income has dropped by 83% year-on-year and by 79% since the previous quarter

What are the main financial stats of INVA

Market
Valuations
Earnings

Shares outstanding

64.09M

Market cap

$925.41M

Enterprise value

$1.19B

Price to earnings (P/E)

17.83

Price to book (P/B)

1.5

Price to sales (P/S)

3.23

EV/EBIT

13.94

EV/EBITDA

10.08

EV/Sales

4.1

Revenue

$290.43M

EBIT

$85.44M

EBITDA

$118.16M

Free cash flow

$116.41M

Per share
Balance sheet
Liquidity

EPS

$0.81

Free cash flow per share

$1.79

Book value per share

$9.64

Revenue per share

$4.47

TBVPS

$14.37

Total assets

$1.19B

Total liabilities

$560.61M

Debt

$445.72M

Equity

$627.49M

Working capital

$268.82M

Debt to equity

0.71

Current ratio

8.43

Quick ratio

6.85

Net debt/EBITDA

2.25

Margins
Efficiency
Dividend

EBITDA margin

40.7%

Gross margin

86.4%

Net margin

17.2%

Operating margin

32.2%

Return on assets

4.3%

Return on equity

8.6%

Return on invested capital

7.7%

Return on capital employed

7.4%

Return on sales

29.4%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Innoviva stock price performed over time

Intraday

-1.7%

1 week

5.48%

1 month

5.79%

1 year

10.14%

YTD

8.98%

QTD

11.16%

How have Innoviva's revenue and profit performed over time

Revenue

$290.43M

Gross profit

$250.8M

Operating income

$93.63M

Net income

$49.88M

Gross margin

86.4%

Net margin

17.2%

INVA's net income has dropped by 83% year-on-year and by 79% since the previous quarter

INVA's operating income has shrunk by 83% YoY and by 74% QoQ

The net margin has plunged by 79% from the previous quarter and by 78% YoY

The operating margin has plunged by 78% YoY and by 74% from the previous quarter

What is Innoviva's growth rate over time

What is Innoviva stock price valuation

P/E

17.83

P/B

1.5

P/S

3.23

EV/EBIT

13.94

EV/EBITDA

10.08

EV/Sales

4.1

The stock's price to earnings (P/E) is 158% more than its last 4 quarters average of 6.9

The company's EPS has shrunk by 81% YoY and by 76% QoQ

The P/B is 57% below the 5-year quarterly average of 3.5

The equity has increased by 13% since the previous quarter but it has declined by 2.2% year-on-year

The revenue has contracted by 22% YoY

The P/S is 20% higher than the last 4 quarters average of 2.7 but 15% lower than the 5-year quarterly average of 3.8

How efficient is Innoviva business performance

INVA's return on equity has dropped by 87% year-on-year and by 79% since the previous quarter

INVA's ROA has plunged by 83% YoY and by 78% from the previous quarter

The return on invested capital has dropped by 77% year-on-year and by 74% since the previous quarter

The company's return on sales has shrunk by 74% QoQ and by 71% YoY

What is INVA's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for INVA.

How did Innoviva financials performed over time

The total assets is 112% greater than the total liabilities

The total liabilities has decreased by 18% YoY

The total assets has declined by 11% year-on-year but it rose by 6% since the previous quarter

The debt is 29% less than the equity

The debt has contracted by 17% YoY

The debt to equity has declined by 15% year-on-year and by 11% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.